Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2016-05-10 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of a specific date (April 29, 2016). This type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, which are components of the capital structure, although it is a recurring monthly disclosure rather than a one-time change announcement. Given the specific nature of reporting total voting rights monthly, it is a specialized regulatory filing. However, since it explicitly details the 'Total number of shares' and 'Total number of voting rights', SHA is the most appropriate category for capital structure reporting.
2016-05-10 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). The content provides a table detailing the total number of shares and voting rights as of a specific date (April 29, 2016). This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing, often related to capital changes or major shareholdings, but the structure strongly aligns with mandatory disclosures about the capital base. Given the options, this is a specific regulatory disclosure about the capital structure. While 'SHA' (Share Issue/Capital Change) is related, this is a routine monthly disclosure of the *current* total, not an announcement of a new issue or change event. 'MRQ' (Major Shareholding Notification) is about changes in ownership thresholds. Since this is a routine, mandatory disclosure about the total number of shares and voting rights, it fits best under a general regulatory filing category if a more specific one isn't available. However, the closest fit among the provided codes that deals directly with the composition of the capital base and voting rights is 'SHA' (Share Issue/Capital Change), as these figures are the foundation for such changes, or 'RNS' (Regulatory Filings) as a general catch-all. Given the focus on the total number of shares and voting rights, which is a fundamental component of capital structure reporting, 'SHA' is a plausible fit, but 'RNS' is safer for routine regulatory updates not explicitly covered. Reviewing the definitions, none perfectly match a 'Total Voting Rights Disclosure'. Since it is a mandatory regulatory disclosure, 'RNS' is the most appropriate fallback, although it is highly specific regulatory data.
2016-05-10 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document text announces a strategic partnership between Oncodesign and Ipsen regarding oncology research and the integration of Oncodesign teams into Ipsen's campus. It details the terms of the collaboration, including minimum guaranteed payments and variable compensation based on activity volume. This type of announcement, detailing a significant business agreement, partnership, or strategic alliance that impacts future operations and potentially financing/R&D direction, fits best under the 'Capital/Financing Update' (CAP) if it involves significant capital structure changes or fundraising, or 'Regulatory Filings' (RNS) if it's a general corporate event disclosure. Since this is a major strategic partnership announcement detailing collaboration terms and integration, it is a significant corporate event disclosure. Given the options, and that it is not a standard financial report (10-K, IR, ER), nor a management change (MANG), nor a specific transaction (POS, TAR), it is best classified as a general corporate announcement. However, the nature of the agreement involves future revenue streams and resource allocation, which sometimes overlaps with financing/capital activities, but the core is a business deal. In the absence of a specific 'Partnership Announcement' code, and since it is a detailed announcement of a significant business development rather than a short notice of a report release (RPA), the most appropriate general category for significant corporate news that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as it is a material event disclosure. If the partnership involved a direct investment or financing, CAP might apply, but here it's a service/collaboration agreement. I will use RNS as the best fit for a material, non-standard corporate event disclosure.
2016-05-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated May 3, 2016, announcing a strategic partnership between Oncodesign and Ipsen in oncology. It details the terms of the collaboration, quotes executives, and includes 'About' sections for both companies. This type of announcement, detailing a significant business development (a partnership/collaboration agreement), does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement regarding business strategy and operations. Since it is not a formal regulatory filing like a 10-K, nor a specific announcement like a dividend (DIV) or management change (MANG), the most appropriate general category for significant, non-standard corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous official announcements.
2016-05-03 English
Quarterly financial report / First quarter financial report
Earnings Release Classification · 100% confidence The document is a press release from Ipsen reporting its sales for the first quarter of 2016. It provides key financial highlights, sales breakdowns by product and therapeutic area, and confirms financial objectives. It is an initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q1 2016
2016-04-28 English
Information financière du premier trimestre
Earnings Release Classification · 100% confidence The document is a quarterly financial update from Ipsen, titled 'Chiffre d'affaires du Groupe au premier trimestre 2016'. It provides detailed revenue figures, performance analysis by therapeutic area, and financial guidance for the year. It is a primary announcement of quarterly financial results containing substantive financial data, which aligns with the definition of an Earnings Release (ER). Q1 2016
2016-04-28 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.